AbD Serotec expands licence with UK Medical Research Council

Published: 23-Mar-2007
Sustainability Research & Development

AbD Serotec, the Oxford-based research antibody division of MorphoSys, has significantly expanded its license agreement with MRC Technology (MRCT), the technology transfer arm of the UK\'s Medical Research Council (MRC).


AbD Serotec, the Oxford-based research antibody division of MorphoSys, has significantly expanded its license agreement with MRC Technology (MRCT), the technology transfer arm of the UK's Medical Research Council (MRC).

The agreement, which provides AbD Serotec with access to a broad range of hybridoma cell lines as a source of research antibodies, is extended for a further five years, and includes additional products which will be implemented in AbD Serotec's offering. Financial details of the agreement were not disclosed.

The Medical Research Council is a national organisation dedicated to improving human health in the UK and abroad. Hybridoma cells which have been engineered by researchers of the MRC network to produce a desired research antibody in large amounts are out-licensed by MRCT.

AbD Serotec offers more than 10,000 antibodies and immunological reagents, custom monoclonal antibodies developed from the MorphoSys HuCAL library, and large and small scale antibody production and conjugation services.

"Our long-lasting relationship with the Medical Research Council as a source of research antibodies has led to a large number of innovative products for our costumers," said Dr Simon Moroney, ceo of MorphoSys AG. "Sales on all products from this license agreement are of significant value for AbD Serotec, and to be able to continue this long-term relationship with one of the most influential research organisations in Great Britain is thus of significant value for the entire MorphoSys Group."

See more

You may also like

Drug Delivery

Catapult and MRC unite to advance human-based drug evaluation

Read more
Medicines Discovery Catapult and the Medical Research Council (MRC) Centre for Drug Safety Science (CDSS) at the University of Liverpool announce strategic collaboration to develop next generation human cell models

Trending Articles

  1. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  2. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  3. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA
  4. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  5. Ecolab and SCG sign MOU to enhance business competitiveness and drive ESG progress This 5-year MOU underscores how collaboration can turn sustainability commitments into measurable outcomes, accelerating the journey toward Net Zero while strengthening cross-industry competitiveness

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Drug Delivery

Catapult and MRC unite to advance human-based drug evaluation

Medicines Discovery Catapult and the Medical Research Council (MRC) Centre for Drug Safety Science (CDSS) at the University of Liverpool announce strategic collaboration to develop next generation human cell models
Ingredients

£12 million in grants to tackle superbugs in a global context

The researchers will use a range of approaches, from clinical and microbiological to geography, modelling and social sciences, to identify, prioritise and understand the specific problem of AMR across different communities and environments in Kenya, Tanzania, Uganda, Malawi and Thailand
Media

MRC forges two new deals with industry to speed drug discovery

Building on the MRC’s strong track record in establishing innovative collaborations with industry, the MRC has formed partnerships with two global pharmaceutical companies, UCB and AstraZeneca
Research & Development

Scientists uncover tau filament structures from Alzheimer’s

Researchers at the Medical Research Council Laboratory of Molecular Biology have, for the first time, revealed the atomic structures of one of the two types of the abnormal filaments, which lead to Alzheimer's disease
Ingredients

Alzheimer’s advance: early stage study in mice show new drugs that restore memory loss and prolong life

Breakthrough findings demonstrate a possible target and potential drug treatment to restore memory loss and extend life span in mice with neurodegeneration
Recruitment

Director announced to lead UK Dementia Research Institute in London

The director of the UK Dementia Research Institute (UK DRI) has been named as Professor Bart De Strooper, current leader of the Laboratory for the Research of Neurodegenerative Diseases at the University of Leuven and scientific director at VIB (Vlaams Instituut voor Biotechnologie) in Belgium. Professor De Strooper will lead the national institute from UCL
Research & Development

Genetic approach could help identify side-effects at early stages of drug development

Involves identifying genetic variants that mimic the action of a drug on its intended target and then checking in large patient groups whether these variants are associated with risk of other conditions
Subscribe now